Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

21 Dec 2018

Abstract excerpt

// Priya K. Gopalan 1 , Andres Gordillo Villegas 1,5 , Chunxia Cao 1 , Mary Pinder-Schenck 2,6 , Alberto Chiappori 2 , Wei Hou 3,7 , Maria Zajac-Kaye 4 , Alison M. Ivey 1 and Frederic J. Kaye 1 1 Department of Medicine, University of Florida, Gainesville, FL, USA 2 Moffitt Cancer Center, Tampa, FL, USA 3 Department of Biostatistics, University of Florida, Gainesville, FL, USA 4 Department of Anatomy and Cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30647837
DOI: 10.18632/oncotarget.26424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibitionPMID 30647837Read ↗

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibitionSemantic proximity Read ↗

Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.Semantic proximity Read ↗

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNASemantic proximity Read ↗

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.Semantic proximity Read ↗

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancerSemantic proximity Read ↗

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesotheliomaSemantic proximity Read ↗

Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer.Semantic proximity Read ↗

Molecular Pathways: CDK4 Inhibitors for Cancer TherapySemantic proximity Read ↗

Palbociclib induces the apoptosis of lung squamous cell carcinoma cells via Rb-independent STAT3 phosphorylationSemantic proximity Read ↗

MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancerSemantic proximity Read ↗

Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.Semantic proximity Read ↗

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.